文献速递妇科

在IV期子宫内膜癌女性中,与单纯化疗相比,加用放疗能否改善生存?基于NCDB和SEER数据库的分析

Does the addition of radiation improve survival compared to chemotherapy alone in women with stage IV endometrial carcinoma? Analysis of the NCDB and SEER databases.
PubMed 文献 · Gynecol Oncol · 2022-04-22

基于NCDB和SEER数据库2004至2017年17,890例IV期子宫内膜癌患者资料,评估术后化疗基础上加用放疗与总生存的关联。两个数据库中,化疗联合体外放疗均与总生存改善相关(NCDB:HR 0.75,95%CI 0.70–0.79;SEER:HR 0.85,95%CI 0.77–0.94),IVA期获益更明显。

要点

  • IV期患者多数仅接受化疗(NCDB 78.8%,SEER 77.0%)。
  • 化疗联合EBRT较单纯化疗与总生存改善相关,IVA期获益更明显。
  • 除透明细胞癌外,各组织学类型中加用放疗均与总生存改善相关。

核心结论

  • 在NCDB和SEER登记分析中,IV A期和IV B期子宫内膜癌女性采用放疗联合化疗的多模式治疗较单纯化疗与总生存改善相关。

研究设计与样本

  • 查询NCDB和SEER登记库2004至2017年IV期子宫内膜癌患者。
  • 治疗分为单纯化疗、化疗联合体外放疗(EBRT)、化疗联合阴道近距离放疗(VBT)、化疗联合EBRT+VBT。
  • 采用多因素Cox回归模型评估治疗方式与总生存(OS)的关联。
  • 共纳入17,890例(NCDB 12,812例,SEER 5,078例),其中IVA期1,757例(9.8%),IVB期16,133例(90.2%)。

主要发现

  • 多数IV期患者接受单纯化疗(NCDB 78.8%,SEER 77.0%);加用放疗时以EBRT最常见(NCDB 15.8%,SEER 15.4%)。
  • 两个数据库中,化疗基础上加用任何放疗均与OS改善相关。
  • 化疗联合EBRT较单纯化疗生存更好:NCDB HR 0.75(95%CI 0.70–0.79),SEER HR 0.85(95%CI 0.77–0.94)。
  • IVA期患者获益更明显:NCDB HR 0.66(95%CI 0.55–0.79),SEER HR 0.63(95%CI 0.46–0.85)。
  • 组织学分层分析中,除透明细胞癌外,化疗加用放疗与所有组织学类型的OS改善相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether the addition of radiation to adjuvant chemotherapy is associated with improved survival in women with stage IV endometrial cancer following surgery. METHODS: The National Cancer Database (NCDB) and Surveillance, Epidemiology, and End Results Program (SEER) registries were queried for patients with stage IV endometrial cancer from 2004 to 2017. Treatment was categorized as chemotherapy alone, chemotherapy with external beam radiation therapy (EBRT), chemotherapy with vaginal brachytherapy (VBT), or chemotherapy with EBRT+VBT. Multivariable Cox regression models assessed associations between treatment modality and overall survival (OS). RESULTS: This analysis included 17,890 (NCDB: 12,812, SEER: 5078) women with stage IV endometrial cancer, including 1757 (9.8%) with IVA disease and 16,133 (90.2%) with IVB. The majority of stage IV patients received chemotherapy alone (NCDB 78.8%, SEER 77.0%). When radiation was utilized in addition to chemotherapy, EBRT was most common (NCDB 15.8%, SEER: 15.4%). In both databases, use of any radiation in addition to chemotherapy was associated with improved OS. Stage IV patients treated with chemotherapy plus EBRT had better survival than those receiving chemotherapy alone [NCDB: HR 0.75 (95% CI 0.70, 0.79), SEER: HR 0.85 (95% CI 0.77, 0.94)]. This benefit was more pronounced in patients with IVA disease [NCDB: HR 0.66 (95% CI 0.55, 0.79), SEER: HR 0.63 (95% CI 0.46, 0.85)]. In histology-stratified analyses, the addition of radiation to chemotherapy was associated with improved OS in all histologies, except clear cell. CONCLUSIONS: In this analysis of the NCDB and SEER registries, the use of multimodality treatment with radiation and chemotherapy was associated with improved OS compared to chemotherapy alone in women with stage IVA and IVB endometrial cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Barrington DA, Fox B, Meade C, et al. Does the addition of radiation improve survival compared to chemotherapy alone in women with stage IV endometrial carcinoma? Analysis of the NCDB and SEER databases. Gynecol Oncol. 2022. PMID: 35469682. doi:10.1016/j.ygyno.2022.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。